-
Tytuł:
-
Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population.
-
Autorzy:
-
Wang Y; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Han S; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Qin H; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Zheng H; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Jiang B; Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.; Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
Cao Y; China National Clinical Research Center for Neurological Diseases, Beijing, China.; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Gao Y; Neurology, Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China.
Guan L; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Jia Q; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Jiang Y; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Jiao Y; China National Clinical Research Center for Neurological Diseases, Beijing, China.; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Li S; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Li Y; Neurology, Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China.
Li Z; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Liu W; Department of Neurology, Beijing Haidian Hospital, Beijing, China.
Ru X; Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.; Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
Sun D; Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.; Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
Sun H; Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.; Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
Wang P; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Wang T; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Zong L; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Guo L; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Xie X; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Xu Y; Neurology, Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, China.
Xu Y; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Yang X; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Yang Y; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Zhou M; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.; China National Clinical Research Center for Neurological Diseases, Beijing, China.
Wang W; Department of Neuroepidemiology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China .; Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
-
Corporate Authors:
-
Chinese Stroke Association Stroke Council Guideline Writing Committee
-
Źródło:
-
Stroke and vascular neurology [Stroke Vasc Neurol] 2020 Sep; Vol. 5 (3), pp. 270-278. Date of Electronic Publication: 2020 Aug 13.
-
Typ publikacji:
-
Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: London : BMJ, [2016]-
-
MeSH Terms:
-
Risk Reduction Behavior*
Cerebrovascular Disorders/*prevention & control
Evidence-Based Medicine/*standards
Neurology/*standards
Platelet Aggregation Inhibitors/*therapeutic use
Primary Prevention/*standards
Cerebrovascular Disorders/diagnosis ; Cerebrovascular Disorders/epidemiology ; China/epidemiology ; Consensus ; Disability Evaluation ; Humans ; Platelet Aggregation Inhibitors/adverse effects ; Recovery of Function ; Risk Assessment ; Risk Factors ; Treatment Outcome
-
References:
-
N Engl J Med. 2018 Oct 18;379(16):1509-1518. (PMID: 30221597)
J Am Coll Cardiol. 2019 Jun 18;73(23):2915-2929. (PMID: 31196447)
Stroke. 2014 Dec;45(12):3754-832. (PMID: 25355838)
Circulation. 2017 Feb 21;135(8):759-771. (PMID: 28052979)
Lancet. 2019 Feb 2;393(10170):407-415. (PMID: 30712900)
Circulation. 2019 Mar 19;139(12):1483-1492. (PMID: 30586750)
Stroke. 2015 Aug;46(8):2368-400. (PMID: 26089327)
JAMA. 2019 Jan 29;321(4):364-373. (PMID: 30694319)
N Engl J Med. 2018 Oct 18;379(16):1499-1508. (PMID: 30221596)
JAMA. 2019 Jan 22;321(3):277-287. (PMID: 30667501)
N Engl J Med. 2019 Jan 3;380(1):23-32. (PMID: 30415637)
N Engl J Med. 2018 Oct 18;379(16):1529-1539. (PMID: 30146931)
N Engl J Med. 2019 Mar 14;380(11):1022-1032. (PMID: 30865796)
Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. (PMID: 31272931)
N Engl J Med. 2019 Jan 3;380(1):11-22. (PMID: 30415628)
Lancet. 2018 Sep 22;392(10152):1036-1046. (PMID: 30158069)
-
Contributed Indexing:
-
Investigator: Y Wang; J Zhao; Q Dong; A Xu; K Chen; J Ge; LH Li Guo; B Hu; Y Huo; L Ji; X Ji; T Li; L Liu; B Luo; Z Miao; X Niu; B Peng; D Su; B Tang; C Wang; N Wang; S Wang; W Wang; X Wang; Y Wang; S Wu; P Xie; Y Xu; Y Xu; Y Yang; J Zeng; C Zhang; T Zhang; Z Zhang; G Zhao; X Zhao
Keywords: atherosclerosis; blood pressure; platelets; stroke
-
Substance Nomenclature:
-
0 (Platelet Aggregation Inhibitors)
-
Entry Date(s):
-
Date Created: 20200815 Date Completed: 20201110 Latest Revision: 20201110
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC7548516
-
DOI:
-
10.1136/svn-2020-000385
-
PMID:
-
32792457
-
Aim: Cerebrovascular disease is the leading cause of death and disability in China, causing a huge burden among patients and their families. Hence, stroke prevention is critical, especially in the high-risk population. Here, we present the evidence-based guideline suitable for the Chinese population.
Methods: Literature search of PubMed and Cochrane library (from January 1964 to June 2019) was done. After thorough discussion among the writing group members, recommendations were listed and summarised. This guideline was reviewed and discussed by the fellow writing committees of the Chinese Stroke Association's Stroke.
Results: This evidence-based guideline was written in three parts: controlling the risk factors of stroke, utilisation of antiplatelet agents and assessing the risks of first-ever stroke. All recommendations were listed along with the recommending classes and levels of evidence.
Conclusions: This guideline provides recommendations for primary prevention of cerebrovascular disease among high-risk population in China. Controlling related risk factors, appropriately using antiplatelet agents, assessing the risk of developing first-ever stroke should help reduce the rate of cerebrovascular disease in China.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
